BGLC Latest Press Releases

-- March 11, 2026 --

BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard MRD Platform Globe Newswire 8:45 AM

-- February 23, 2026 --

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman Globe Newswire 8:30 AM

-- January 28, 2026 --

BioNexus Launches Regional Deployment of VitaGuard MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market Globe Newswire 9:00 AM

-- December 3, 2025 --

BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard Globe Newswire 8:45 AM

-- December 2, 2025 --

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization Globe Newswire 8:05 AM

-- December 1, 2025 --

BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard MRD Platform as Part of Strategic Alliance with Tongshu Gene Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software